MediWound Ltd. (NASDAQ:MDWD - Free Report) - HC Wainwright lowered their FY2030 EPS estimates for MediWound in a research note issued on Friday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will post earnings per share of $1.95 for the year, down from their previous estimate of $2.25. The consensus estimate for MediWound's current full-year earnings is ($2.37) per share.
MDWD has been the topic of several other research reports. Wall Street Zen raised MediWound from a "strong sell" rating to a "sell" rating in a report on Saturday, September 26th. TD Cowen restated a "buy" rating on shares of MediWound in a research report on Thursday, September 24th. Alliance Global Partners restated a "buy" rating on shares of MediWound in a research note on Wednesday, September 16th. Weiss Ratings cut MediWound from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, September 8th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, MediWound currently has a consensus rating of "Moderate Buy" and a consensus price target of $33.00.
Get Our Latest Stock Analysis on MediWound
MediWound Price Performance
MediWound stock opened at $12.90 on Monday. The business has a 50 day moving average price of $13.20 and a two-hundred day moving average price of $15.05. MediWound has a 12 month low of $11.80 and a 12 month high of $19.70. The stock has a market cap of $167.83 million, a price-to-earnings ratio of -5.84 and a beta of 0.07.
MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.06. MediWound had a negative return on equity of 58.44% and a negative net margin of 234.98%. The firm had revenue of $3.57 million for the quarter, compared to analyst estimates of $6.73 million.
Hedge Funds Weigh In On MediWound
A hedge fund recently bought a new stake in MediWound stock. Marshall Wace LLP bought a new position in shares of MediWound Ltd. (NASDAQ:MDWD - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 15,026 shares of the biopharmaceutical company's stock, valued at approximately $207,000. Marshall Wace LLP owned 0.12% of MediWound at the end of the most recent reporting period. 46.83% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other MediWound news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 9.20% of the stock is currently owned by corporate insiders.
MediWound News Summary
Investors following MDWD have been watching these news items:
- Positive Sentiment: MediWound said its Phase III VALUE trial of EscharEx is advancing, with an interim assessment and enrollment completion expected by the end of Q1 2027. MediWound third-quarter results and corporate update
- Neutral Sentiment: The quarterly loss of $0.65 per share was slightly better than analyst estimates of $0.66–$0.71, but wider than the $0.24 loss reported a year earlier. Zacks Q3 results report
- Negative Sentiment: Revenue was $3.57 million, well below the $6.73 million consensus estimate. Reports attributed the weakness in part to stalled U.S. government work, and said the company dropped its full-year guidance—an unfavorable signal for the near-term outlook. MediWound drops full-year guidance Q3 revenue miss and U.S. government work
MediWound Company Profile
(
Get Free Report)
MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company's lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.